Troponin and brain natriuretic peptides offer better prognostic performance for predicting future events in atrial fibrillation compared with currently available risk scores.
Do biomarkers like troponin and brain natriuretic peptides improve prognostic stratification in patients with atrial fibrillation compared to standard risk scores?
Troponin and brain natriuretic peptides are promising biomarkers for prognostic stratification in atrial fibrillation, potentially outperforming current clinical risk scores.
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmias and associated with the risk of stroke and death. Continuous development of the diagnostic tool and prognostic stratification may lead to optimal management of AF. The use of biomarkers in the management of AF has been grown as an interesting topic. However, the AF biomarkers are not yet well established in the major guidelines. Among these biomarkers, a lot of data show troponin and brain natriuretic peptides are promising for the prediction of future events. The troponin elevation in AF patients may not necessarily be diagnosed as myocardial infarction or significant coronary artery stenosis, and brain natriuretic peptide elevation may not necessarily confirm heart failure. Troponin T and troponin I may predict postoperative AF. Furthermore, troponin and brain natriuretic peptide gave better prognostic performance when compared with the risk score available today.
Ardhianto et al. (Mon,) conducted a review in Atrial fibrillation. Troponin and brain natriuretic peptides vs. Available risk scores was evaluated. Troponin and brain natriuretic peptides offer better prognostic performance for predicting future events in atrial fibrillation compared with currently available risk scores.